$PETS

PetMed Express (PETS) will release its Q2 2026 financial results on Nov. 10 after market close and host a conference call at 4:30 p.m. ET. The company is a direct-to-consumer pet healthcare provider, operating online pharmacies PetMeds and PetCareRx.

PetMed Express granted CEO Jeff Willard 250,000 restricted shares and 250,000 performance share units (PSUs), and CTO Andrew Parry 100,000 restricted shares. The shares vest over three years, with PSUs tied to total shareholder return (TSR) versus the S&P 600 Specialty Retail index.

PETMED EXPRESS INC (PETS) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers Effective September 27, 2026, the Board of Directors of PetMed Express, Inc. (the “Company”) approved an amendment to the Pe

PETMED EXPRESS INC (PETS) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. PetMeds Enhances Board of Directors with Appointment of Tamar Elkeles as New Independent Director Dr. Elkeles Brings Deep Experience and Proven Track Record in Shaping Human Capital Strategy to Support Strategic Growth and Operational Execution DELRAY BEACH, Fla., September 21, 2

PetMed Express (PETS) named Jeff Willard as CEO and President, effective September 28, 2026. Willard succeeds Leslie Campbell, who will retire as Board Chair. Willard has 25 years of leadership experience in consumer and e-commerce. The company aims to return to profitability and growth. PETS stock traded between $1.57 and $4.10 in the past year, closing at $4.10 on Wednesday.

PETMED EXPRESS INC (PETS) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. PetMeds Appoints Jeff Willard as CEO & President and Announces Board Leadership Transition Justin Mennen to Succeed Leslie C.G. Campbell as Chair of the Board Following Her Retirement DELRAY BEACH, Fla., September 17, 2026 — PetMed Express, Inc., dba PetMeds and parent company of

PetMed Express reported Q1 2027 net sales of $41M, down 19.9% YoY, with a net loss of $6.1M. Key highlights include a $37M sale-leaseback deal, a partnership with Rural King, and an unsolicited acquisition offer of $3 per share. Management emphasized expense management and new revenue channels. Net sales stabilized above $40M sequentially, despite prescription sales declines.

PetMed Express, Inc. reported a Q1 2027 earnings call focused on shifting customer acquisition to diversified B2B and white-label offerings, after completing an SAP ERP rollout and new call center platform. Management cited a 15% acquisition cost reduction, delivery times improved up to 2 days, and recurring auto-ship and memberships at 61.5% of gross sales. Net loss was $6.1 million. It also disclosed an unsolicited $3/share acquisition proposal and a pending $37 million sale-leaseback.

PETMED EXPRESS INC (PETS) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 PetMeds® Announces First Quarter Financial Results Delray Beach, Florida, August 13, 2026, PetMed Express, Inc. dba PetMeds and parent company of PetCareRx (NASDAQ: PETS) today announced its financial results for its first quarter ended June 30, 2026. Quarterly Highl

PETMED EXPRESS INC (PETS) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers On August 11, 2026, the shareholders of PetMed Express, Inc. (the “Company”), upon recommendation of the Company’s Board of